Unlike prescription GLP-1 medications, these patches have not undergone rigorous clinical trials to prove their safety, effectiveness, or ability to deliver active ingredients through the skin
What This Regulatory Difference Means for Patients Patients considering compounded weight loss medications should understand that these products, although prepared by licensed pharmacies using pharmaceutical ingredients, have not been evaluated by the FDA as finished drugs
In a wet environment (diarrhea), it absorbs excess liquid
The joint advisory from four major medical organizations recommends 1.2-1.6 g/kg/day of protein during active weight reduction with GLP-1 therapy
Differences in study design, together with the relatively small number of participants receiving combined treatment, may limit the ability to detect synergistic effects
Long available for type 2 diabetes, the GLP-1 agonists expanded into weight management with approval of Saxenda (liraglutide) by the United States Food and Drug Administration (FDA) in 2014